Compare CENT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | MESO |
|---|---|---|
| Founded | 1955 | 2004 |
| Country | United States | Australia |
| Employees | N/A | 81 |
| Industry | Consumer Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | N/A |
| Metric | CENT | MESO |
|---|---|---|
| Price | $39.33 | $16.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | 69.9K | ★ 171.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.60 | $633.98 |
| Revenue Next Year | $2.04 | $29.51 |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.77 | $9.61 |
| 52 Week High | $41.25 | $21.50 |
| Indicator | CENT | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 65.96 | 47.03 |
| Support Level | $31.65 | $16.74 |
| Resistance Level | $40.81 | $17.48 |
| Average True Range (ATR) | 1.44 | 0.46 |
| MACD | 0.12 | -0.00 |
| Stochastic Oscillator | 84.73 | 49.82 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.